Sunbelt Securities’s ImmunityBio IBRX Stock Holding History

Sunbelt Securities’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$138	Hold	18	–	–	﹤0.01%	2582
2025 Q4	$36	Buy	+18	New	+$41	﹤0.01%	2677

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Sunbelt Securities's IBRX Position: Q1 2026 in Review

Sunbelt Securities held its ImmunityBio (IBRX) position steady in Q1 2026 at 18 shares worth $138. The position accounts for ﹤0.01% of the portfolio, ranked #2582.

Sunbelt Securities first reported a position in IBRX in Q4 2025 and has held it in 2 quarters since. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

Sunbelt Securities held 18 shares of ImmunityBio worth $138 as of Q1 2026.
Sunbelt Securities left its ImmunityBio share count unchanged in Q1 2026.
ImmunityBio made up ﹤0.01% of Sunbelt Securities's portfolio in Q1 2026, its #2582 holding.
Sunbelt Securities first reported a position in ImmunityBio in Q4 2025 and has held it in 2 quarters since.
386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Sunbelt Securities's 13F filing for Q1 2026, filed 18 May 2026.